Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by CNBC Top News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersLieutenant General Brett Sylvia was removed as head of strategy, plans and policy on the Joint Chiefs of Staff.
By Michael·13m ago
Why it mattersMicrosoft and Alphabet both reported capital expenditures that fell short of estimates, adding to concern over the cost of the AI build-out.
By Michael·8m ago
Why it mattersWall Street hammered Alphabet for an earnings miss that included weaker-than-expected revenue out of the company's core business.
By Michael·9m ago
Why it mattersRussia is trying to develop is own version of the satellite constellation Starlink: Rassvet.
By Michael·1h ago